0001415889-24-009532.txt : 20240401
0001415889-24-009532.hdr.sgml : 20240401
20240401161423
ACCESSION NUMBER: 0001415889-24-009532
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240328
FILED AS OF DATE: 20240401
DATE AS OF CHANGE: 20240401
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Allan Jonathan
CENTRAL INDEX KEY: 0001966716
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38938
FILM NUMBER: 24809409
MAIL ADDRESS:
STREET 1: C/O STOKE THERAPEUTICS, INC.
STREET 2: 45 WIGGINS AVENUE
CITY: BEDFORD
STATE: MA
ZIP: 01730
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Stoke Therapeutics, Inc.
CENTRAL INDEX KEY: 0001623526
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 471144582
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 45 WIGGINS AVENUE
CITY: BEDFORD
STATE: MA
ZIP: 01730
BUSINESS PHONE: 781-430-8200
MAIL ADDRESS:
STREET 1: 45 WIGGINS AVENUE
CITY: BEDFORD
STATE: MA
ZIP: 01730
FORMER COMPANY:
FORMER CONFORMED NAME: ASOthera Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141028
4
1
form4-04012024_080416.xml
X0508
4
2024-03-28
0001623526
Stoke Therapeutics, Inc.
STOK
0001966716
Allan Jonathan
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
BEDFORD
MA
01730
false
true
false
false
GENERAL COUNSEL & CORP SEC
1
Common Stock
2024-03-28
4
S
0
5026
13.1888
D
2698
D
Common Stock
2024-03-28
4
S
0
100
13.81
D
2598
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 15, 2023 by the reporting person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.62 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
/s/ Stephen Tulipano, Attorney-in-Fact
2024-04-01